Editor's Note: An earlier version misstated that iRhythm had not responded; the company provided a statement on Aug. 18. The short-seller argued that investors are overlooking regulatory, competitive, ...
iRhythm Technologies today unveiled initial findings on the post-market and real-world performance of its Zio monitor, building on the devices previous generation of the long-term continuous ...
iRhythm is launching its next generation long-term ambulatory cardiac monitor in the U.S. The new Zio monitor is a prescription-only ECG monitor, which is an integral part of the Zio LTCM service. The ...
Based in San Francisco, CA, iRhythm is a medical technology and services company that supplies ambulatory cardiac monitors used to detect arrhythmias and other cardiac abnormalities that can indicate ...
iRhythm Technologies, Inc. IRTC has received regulatory approval from Japan’s Pharmaceutical and Medical Device Agency for its Zio long-term continuous ECG monitoring (LTCM) system. The Zio system, ...
SAN FRANCISCO, Sept. 26, 2023 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC) today announced the U.S. launch of its next-generation Zio® monitor and enhanced Zio® long-term continuous ...
Provides Evidence From Interpreting Legal Filings That the Department of Justice Is Investigating a Possible Cover-up by iRhythm Management Related to Potentially Fatal Product Flaws Raises Serious ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback